Sequana Medical’s ALFApump® System proves to be a safe and efficacious

Zurich, Switzerland: 20 April 2012 - Sequana Medical announced that initial results from the PIONEER Clinical Study of its ALFApump System were presented today at the 47th annual European Association for Study of the Liver Meeting in Barcelona. The data demonstrated that the ALFApump System is a safe and effective device for management of ascites in patients with advanced cirrhosis. The PIONEER study is a prospective, multi-centre, open label study of patients with refractory ascites due to liver cirrhosis conducted at nine centres in four European countries. Sequana Medical's ALFApump System is the first and only system for the automatic and continual removal of ascites. Refractory ascites affects over 100,000 patients in Europe and the US every year and the number of patients is growing at an annual rate of 10% due to the accelerating incidence of hepatitis and obesity-related liver disease.

More info on the press release or on Sequana's website.